Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy

Brachytherapy

Volumn 9, Issue 1, 2010, Pages 42-49

  Taira, Al V ^a   Merrick, Gregory S ^b,c   Galbreath, Robert W ^b,c   Butler, Wayne M ^b,c   Wallner, Kent E ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WHEELING HOSPITAL   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Androgen deprivation therapy; Overall survival; Prostate cancer; Testosterone

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; TESTOSTERONE;

ADULT; ADVERSE OUTCOME; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; DRUG EFFECT; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGE DISTRIBUTION; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TESTOSTERONE; WASHINGTON;

EID: 72449190050     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.06.008     Document Type: Article

References (28)

1. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
2. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
3. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
4. Stock R.G., Ho A., Cesaretti J.A., and Stone N.N. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
5. Milosevic M., Chung P., Parker C., et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 67 (2007) 6022-6025
6. Pinthus J.H., Bryskin I., Trachtenberg J., et al. Androgen induces adaptation to oxidative stress in prostate cancer: Implications for treatment with radiation therapy. Neoplasia 9 (2007) 68-80
7. Hakimian P., Blute Jr. M., Kashanian J., et al. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int 102 (2008) 1509-1514
8. Harle L.K., Maggio M., Shahani S., et al. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4 (2006) 687-696
9. Isbarn H., Boccon-Gibod L., Carroll P.R., et al. Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks. Eur Urol 55 (2009) 62-75
10. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299 (2008) 289-295
11. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
12. Dosoretz A.M., Chen M.H., Salenius S.A., et al. Mortality in men age 70 or more with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormonal therapy. Int J Radiat Oncol Biol Phys 72 (2008) s39
13. Taira A.V., Merrick G.S., Galbreath R.W., et al. Pretreatment serum testosterone and androgen deprivation: Effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys 74 (2009) 1143-1149
14. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol 6 (2000) 78-84
15. Crawford E.D., Barqawi A.B., O'Donnell C., et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 100 (2007) 509-513
16. Bittner N., Merrick G.S., Galbreath R.W., et al. Primary causes of death after permanent prostate brachythearpy. Int J Radiat Oncol Biol Phys 72 (2008) 433-440
17. Ding E.L., Song Y., Malik V.S., et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295 (2006) 1288-1299
18. Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116 (2007) 2694-2701
19. Laughlin G.A., Barrett-Connor E., and Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93 (2008) 68-75
20. Matsumoto A.M. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 57 (2002) M76-M99
21. Shores M.M., Matsumoto A.M., Sloan K.L., et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 (2006) 1660-1665
22. Bolla M., Collette L., van Tienhoven G., et al. Ten year results of long term adjuvant androgen deprivation with goserlin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study. Int J Radiat Oncol Biol Phys 72 (2008) s30
23. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27 (2009) 92-99
24. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
25. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54 (2008) 816-823
26. Silverman J.S., Ruth K., Horwitz E.M., et al. Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy. Int J Radiat Oncol Biol Phys 72 (2008) s75-s76
27. Petit J.H., Gluck C., Kiger W.S., et al. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy 5 (2007) 256-261
28. Gibbons E.P., Jacobs B.L., Smith R.P., et al. Dosimetric outcomes in prostate brachytherapy: Is downsizing the prostate with androgen deprivation necessary?. Brachytherapy 8 (2009) 304-308